This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harlan, L. C. Articles by Ballard-Barbash, R. Search for Related Content PubMed PubMed Citation Articles by Harlan, L. C. Articles by Ballard-Barbash, R. Social Bookmarking                            What's this?

Adjuvant Therapy for Breast Cancer: Practice Patterns of Community Physicians

From the National Cancer Institute, Bethesda, and Information Management Services, Inc, Silver Spring, MD.

Address reprint requests to Linda C. Harlan, MD, Applied Research Program, National Cancer Institute, 6130 Executive Blvd, EPN 4005, Bethesda, MD 20892; email: lh50w{at}nih.gov

PURPOSE: We evaluated the use of adjuvant therapy for breast cancer using the National Institutes of Health (NIH) Consensus Development Conference statements as guideposts for assessing how rapidly community physicians adopt recommended therapies.

PATIENTS AND METHODS: Women with stage I through IIIA breast cancer diagnosed in 1987 through 1991 and in 1995 were randomly sampled from the population-based National Cancer Institute Surveillance, Epidemiology, and End-Results program. A total of 8,106 women were included in the study with younger women, 50 years, being oversampled. Their treating physicians were asked to verify whether chemotherapy, hormonal therapy, or both were given.

RESULTS: After adjusting for clinical and nonclinical factors, the use of 1985 recommendations for adjuvant therapy in women with node-positive disease was already high at 80% in 1987 and increased slightly to 84% by 1995. Use of combined multidrug chemotherapy plus tamoxifen increased. In contrast, the use of 1990 recommendations for adjuvant therapy for node-negative disease was slightly less than 13% in 1987 and increased markedly to 57% by 1995. For women with node-negative tumors 1 cm in size diagnosed in 1995, 40% received tamoxifen, 16% combination chemotherapy, and 7% both, an increase from 10%, 5%, and 0.4%, respectively, in 1987.

CONCLUSION: Community physicians began prescribing adjuvant chemotherapy and hormonal therapy in advance of publication of the NIH consensus statement in 1990. Adoption of recommended treatments for node-negative disease has been less complete compared with node-positive tumors, perhaps reflecting the more complex nature of the clinical trials data or the smaller anticipated benefit from adjuvant therapy for this disease subset.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Magai, N. S. Consedine, B. A. Adjei, D. Hershman, and A. Neugut Psychosocial Influences on Suboptimal Adjuvant Breast Cancer Treatment Adherence Among African American Women: Implications for Education and Intervention Health Educ Behav, December 1, 2008; 35(6): 835 - 854. [Abstract] [PDF]

				M. J. Hassett, M. E. Hughes, J. C. Niland, S. B. Edge, R. L. Theriault, Y.-N. Wong, J. Wilson, W. B. Carter, D. W. Blayney, and J. C. Weeks Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer J. Clin. Oncol., December 1, 2008; 26(34): 5553 - 5560. [Abstract] [Full Text] [PDF]

				Y. H. Ju, D. R. Doerge, K. A. Woodling, J. A. Hartman, J. Kwak, and W. G. Helferich Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo Carcinogenesis, November 1, 2008; 29(11): 2162 - 2168. [Abstract] [Full Text] [PDF]

				K. A. Vanderveen, D. A. Paterniti, R. L. Kravitz, and R. J. Bold Diffusion of Surgical Techniques in Early Stage Breast Cancer: Variables Related to Adoption and Implementation of Sentinel Lymph Node Biopsy Ann. Surg. Oncol., May 1, 2007; 14(5): 1662 - 1669. [Abstract] [Full Text] [PDF]

				K. D. Crew, A. I. Neugut, X. Wang, J. S. Jacobson, V. R. Grann, G. Raptis, and D. L. Hershman Racial Disparities in Treatment and Survival of Male Breast Cancer J. Clin. Oncol., March 20, 2007; 25(9): 1089 - 1098. [Abstract] [Full Text] [PDF]

				S. E. Lillie, N. T. Brewer, S. C. O'Neill, E. F. Morrill, E. C. Dees, L. A. Carey, and B. K. Rimer Retention and Use of Breast Cancer Recurrence Risk Information from Genomic Tests: The Role of Health Literacy Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 249 - 255. [Abstract] [Full Text] [PDF]

				S. S. Gorin, J. E. Heck, B. Cheng, and S. J. Smith Delays in breast cancer diagnosis and treatment by racial/ethnic group. Arch Intern Med, November 13, 2006; 166(20): 2244 - 2252. [Abstract] [Full Text] [PDF]

				A. B. Mariotto, E. J. Feuer, L. C. Harlan, and J. Abrams Chapter 2: Dissemination of Adjuvant Multiagent Chemotherapy and Tamoxifen for Breast Cancer in the United States Using Estrogen Receptor Information: 1975-1999 J Natl Cancer Inst Monographs, October 1, 2006; 2006(36): 7 - 15. [Abstract] [Full Text] [PDF]

				Y. H. Ju, K. F. Allred, C. D. Allred, and W. G. Helferich Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations Carcinogenesis, June 1, 2006; 27(6): 1292 - 1299. [Abstract] [Full Text] [PDF]

				J. J. Dignam The Ongoing Search for the Sources of the Breast Cancer Survival Disparity J. Clin. Oncol., March 20, 2006; 24(9): 1326 - 1328. [Full Text] [PDF]

				L. C. Harlan, L. X. Clegg, J. Abrams, J. L. Stevens, and R. Ballard-Barbash Community-Based Use of Chemotherapy and Hormonal Therapy for Early-Stage Breast Cancer: 1987-2000 J. Clin. Oncol., February 20, 2006; 24(6): 872 - 877. [Abstract] [Full Text] [PDF]

				S. L.B. Miller, L. E. Jones, and C. P. Carney Psychiatric Sequelae Following Breast Cancer Chemotherapy: A Pilot Study Using Claims Data Psychosomatics, December 1, 2005; 46(6): 517 - 522. [Abstract] [Full Text] [PDF]

				J. J. Doyle, A. I. Neugut, J. S. Jacobson, V. R. Grann, and D. L. Hershman Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study J. Clin. Oncol., December 1, 2005; 23(34): 8597 - 8605. [Abstract] [Full Text] [PDF]

				D. A. Berry, K. A. Cronin, S. K. Plevritis, D. G. Fryback, L. Clarke, M. Zelen, J. S. Mandelblatt, A. Y. Yakovlev, J. D. F. Habbema, E. J. Feuer, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med., October 27, 2005; 353(17): 1784 - 1792. [Abstract] [Full Text] [PDF]

				B. K. Edwards, M. L. Brown, P. A. Wingo, H. L. Howe, E. Ward, L. A. G. Ries, D. Schrag, P. M. Jamison, A. Jemal, X. C. Wu, et al. Annual Report to the Nation on the Status of Cancer, 1975-2002, Featuring Population-Based Trends in Cancer Treatment J Natl Cancer Inst, October 5, 2005; 97(19): 1407 - 1427. [Abstract] [Full Text] [PDF]

				X. L. Du, D. V. Jones, and D. Zhang Effectiveness of Adjuvant Chemotherapy for Node-Positive Operable Breast Cancer in Older Women J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2005; 60(9): 1137 - 1144. [Abstract] [Full Text] [PDF]

				J. S. Mandelblatt, C. B. Schechter, K. R. Yabroff, W. Lawrence, J. Dignam, P. Muennig, Y. Chavez, J. Cullen, and M. Fahs Benefits and Costs of Interventions to Improve Breast Cancer Outcomes in African American Women J. Clin. Oncol., July 1, 2004; 22(13): 2554 - 2566. [Abstract] [Full Text] [PDF]

				L. C. Harlan, L. X. Clegg, and J. L. Warren Chemotherapy in Women with Breast Cancer Ann Intern Med, November 18, 2003; 139(10): 868 - 868. [Full Text] [PDF]

				X. L. Du and C. R. Key Chemotherapy in Women with Breast Cancer Ann Intern Med, November 18, 2003; 139(10): 868 - 869. [Full Text] [PDF]

				L. C. Harlan, L. X. Clegg, and E. L. Trimble Trends in Surgery and Chemotherapy for Women Diagnosed With Ovarian Cancer in the United States J. Clin. Oncol., September 15, 2003; 21(18): 3488 - 3494. [Abstract] [Full Text] [PDF]

				H. K. Weir, M. J. Thun, B. F. Hankey, L. A. G. Ries, H. L. Howe, P. A. Wingo, A. Jemal, E. Ward, R. N. Anderson, and B. K. Edwards Annual Report to the Nation on the Status of Cancer, 1975-2000, Featuring the Uses of Surveillance Data for Cancer Prevention and Control J Natl Cancer Inst, September 3, 2003; 95(17): 1276 - 1299. [Abstract] [Full Text] [PDF]

				X. L. Du Re: Trends in Use of Adjuvant Multi-Agent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 1975-1999 J Natl Cancer Inst, May 7, 2003; 95(9): 683 - 683. [Full Text] [PDF]

				A. Mariotto, E. J. Feuer, L. C. Harlan, L.-M. Wun, K. A. Johnson, and J. Abrams Trends in Use of Adjuvant Multi-Agent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 1975-1999 J Natl Cancer Inst, November 6, 2002; 94(21): 1626 - 1634. [Abstract] [Full Text] [PDF]